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Abstract
Purpose: Phase 1 trials play a crucial role in oncology by translating laboratory science into efficient therapies. Molecular
targeted agents (MTA) differ from traditional cytotoxics in terms of both efficacy and toxicity profiles. Recent reports
suggest that higher doses are not essential to produce the optimal anti-tumor effect. This study aimed to assess if MTA
could achieve clinical benefit at much lower dose than traditional cytotoxics in dose seeking phase 1 trials.
Patients and Methods: We reviewed 317 recent phase 1 oncology trials reported in the literature between January 1997
and January 2009. First sign of efficacy, maximum tolerated dose (MTD) and their associated dose level were recorded in
each trial.
Results: Trials investigating conventional cytotoxics alone, MTA alone and combination of both represented respectively
63.0% (201/317), 23.3% (74/317) and 13.7% (42/317) of all trials. The MTD was reached in 65.9% (209/317) of all trials and
was mostly observed at the fifth dose level. First sign of efficacy was less frequently observed at the first three dose-levels
for MTA as compared to conventional cytotoxics or combinations regimens (48.3% versus 63.2% and 61.3%). Sign of efficacy
was observed in the same proportion whatever the treatment type (73–82%). MTD was less frequently established in trials
investigating MTA alone (51.3%) or combinations (42.8%) as compared to conventional cytotoxic agents (75.6%).
Conclusion: First sign of efficacy was less frequently reported at the early dose-levels and MTD was less frequently reached
in trials investigating molecular targeted therapy alone. Similar proportion of trials reported clinical benefit.
Citation: Ferte C, Soria J-C, Penel N (2011) Dose-Levels and First Signs of Efficacy in Contemporary Oncology Phase 1 Clinical Trials. PLoS ONE 6(3): e16633.
doi:10.1371/journal.pone.0016633
Editor: Zvia Agur, Institute for Medical Biomathematics, Israel
Received August 5, 2010; Accepted January 7, 2011; Published March 2, 2011
Copyright:  2011 Ferte et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: chferte@hotmail.com
Introduction
Phase 1 oncology trials play a crucial role in translating
laboratory science into effective therapies. These trials enroll
patients with advanced cancer that have mostly exhausted all
available standard care, in order to evaluate the safety profile and
the pharmacokinetic properties of new therapeutic regimens. The
primary aim of such studies remains to establish the optimal
recommended dose for further trials. Traditional phase 1 oncology
trials consist in the administration of increasing doses of the
experimental compound to successive cohorts of patients until the
maximal tolerated dose is reached. This design was developed in
the context of the conventional cytotoxic agents, which exhibit
dose-efficacy and dose-toxicity relationships. The highest dose
patients could tolerate was thought to produce the greatest benefit
[1–2]. Therefore, the conventional metric and endpoint to
determine the optimal phase 2 recommended dose is the
experienced toxicity [3].
The recent increase in the knowledge of molecular mechanisms
implicated in cancer growth led to the emergence of a vast number
of novel therapeutic agents (i.e.: monoclonal antibodies, tyrosine
kinase inhibitors, proteasome inhibitors, demethylating agents,
pro-apoptotic agents…). This new class of agents demonstrated
very different toxicity and efficacy profiles compared to traditional
cytotoxics. It has been advocated that MTD would not be the best
approach to generate the maximum anti-tumor effect [4–5].
Molecular targeted agents might then achieve clinical benefit at
lower dose levels than those required with conventional cytotoxic
agents. To further gain insight on this topic, we reviewed 317
recent phase 1 oncology trials, in order to evaluate if the clinical
benefit is observed at lower doses with molecular targeted
therapies compared to conventional cytotoxic agents.
Materials and Methods
Selection of publications
The reports considered for the present study were found by
searches of Medline using the terms: ‘‘clinical trial, phase I’’, ‘‘solid
tumors’’. References were selected from the following oncology
journals that usually deal with phase I trials: Annals of Oncology,
European Journal of Cancer, Journal of Clinical Oncology, Clinical Cancer
Research and Investigational New Drugs. Only articles published in
English between 1997, January and 2009, January were included.
The most frequently tested agents were identified and assessed for
relevance by use of the following parameters: Only phase 1 studies
investigating systemic treatments with dose seeking were selected,
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loco-regional treatments (e.g. intra-peritoneal injections) trials and
organ impairment studies were excluded. A total of three hundred
and five publications reporting 317 dose-seeking phase-I-trials
were finally herein analyzed.
Data extraction and definitions
The following pieces of information were extracted: date of
publication, type of treatments (cytotoxic agents, molecular-
targeted agent and combination of both), number of explored
dose-levels, dose-level associated with maximal tolerated dose and
dose level associated with first signs of efficacy. The maximal
tolerated dose (MTD) was defined as the dose where a pre-
specified number of patients (usually 2 of 3 or 2 of 6) exhibits dose-
limiting toxicity. The first evaluation was mostly scheduled after
two cycles of treatment. Sign of efficacy was defined as complete
response (CR) or partial response (PR) as well as stable disease
(SD) (according to validated criteria such as RECIST or WHO) or
long-lasting stable disease (defined as either CR or PR or SD . 3
months [6]).
Statistical analysis
The description of the results was based on classical statistical
methods: median and range, mean and standard derivation,
percentage and 95%-confidence intervals (95%-CI). Comparisons
used Mann-Whitney test for continuous variables and Fischer
exact test for categorical variables. P-values were done when the
test had shown a significant difference (p,0.05). The collected
data were analyzed using SPSS version 13.0 statistical software.
Results
General
The sample included the results of 317 phase 1 oncology trials
published between January 1997 and January 2009 (Figure 1).
Trials of conventional cytotoxic agent(s) alone accounted for
63.0% (201/317) of all trials. Trials investigating molecular
targeted therapies alone represented 23.3% (74/317) of all trials.
Trials investigating a combination of conventional cytotoxic agents
and molecular targeted therapies accounted for 13.7% (42/317) of
all trials. The MTD was established in 65.9% (209/317) of all
trials. The formal MTD was not established at the end of the trial
in 25.2% of all studies (80/317). No clear MTD data was reported
in 28 reports (8.9%). The median number of tested dose-levels was
five in all treatment categories (Table 1). In most cases, MTD was
reached at the fifth dose level. A total of 253/317 trials (79.8%)
exhibited signs of drug activity. The dose level associated with first
sign of efficacy was reported in 170/253 trials (67.2%): median 1,
range 1–9.
Comparison according to treatment categories
MTD was less frequently reached in trials investigating targeted
therapies alone (51.3%) or the combinations (42.8%) compared to
conventional cytotoxic agents (75.6%) (p,0.0001, Fischer exact
test). Sign of efficacy was observed at the same proportion in the 3
treatment categories: 82.0% for conventional cytotoxic agent,
78.3% for molecular targeted therapies and 73.8% for their
combinations. First sign of efficacy was observed in most cases at
the first or second dose-level. First sign of efficacy was less
frequently observed at the first dose-level for molecular targeted
therapies (25.0%) compared to conventional cytotoxic agents
(52.2%) or their combinations (51.6%) (p,0.0001, Fischer exact
test). It was also less frequently observed at the three first dose-
levels of trials testing molecular targeted therapies alone (48.3%
versus 63.2% and 61.3%) (p,0.0001, Fischer exact test). The first
sign of efficacy was observed before the MTD with the same
proportion (52%–63.2%) whatever the treatment categories. But,
the trials investigating combinations reached sign of efficacy
without establishing MTD in the largest proportion as compared
to those investigating conventional cytotoxics or molecular
targeted agents alone (65% versus 13.4% and 15.0%) (p,0.05).
Discussion
We observed that first signs of efficacy were less frequently
reported at early dose levels in MTA phase 1 trials than in
conventional cytotoxics ones. These findings are in apparent
contradiction with Postel-Vinay et al. and Jain et al., which
described similar rates of clinical benefit whatever the tested dose
of the MTA [6–7]. Both authors used empiric cut-offs based on the
percentage of MTD to partition the patients. Such methodology
may be sub-optimal since the escalating dose design is generally
not linear (e.g.: Fibonacci escalation). This reason led us to
propose a more precise analysis based on the dose level rather than
on the percentage of MTD. We hypothesize that the choice of very
conservative starting dose and the use of unsuitable dose-escalation
rules mainly explain why first signs of efficacy were less frequently
observed at early dose-levels in MTA trials. Regarding the starting
dose, the translation rules from animal to man are rough (the usual
starting dose is calculated based on the tenth of the animal LD10)
and no recent studies yet addressed this question regarding the
MTA setting [8–11]. The Health Authorities also favor very
conservative approaches, with very low starting doses. Moreover,
the classical dose escalation rules (i.e. Fibonacci escalation, 3+3
design, dose-effect and dose-toxicity relationships) may not be
suitable for MTA phase 1 trials. Most of dose-seeking phase 1 trials
investigating MTA are designed with the same underlying
assumptions as those made for traditional cytotoxics phase 1
trials: (i) a higher dose is preferred, if tolerable, since it would
produce more tumor shrinkage [1–2] (ii) the main metric to
establish the phase-2-recommended dose is then the experienced
toxicity [12–13]. However, both the absence of dose-effect
relationship [6–7] and the trend towards long lasting stable
disease rather than tumor shrinkage [4–5] were observed in the
MTA setting. New designs need to be more largely explored, such
as accelerated titration design and continual reassessment method,
which could allow more rapid dose-escalation and reduce the
number of patients treated with infra-therapeutic dose-levels [14].
Our results also pointed out that MTD was less frequently
identified in MTA phase 1 trials. The pertinence of establishing
MTD for MTA is debatable. On the first hand, the toxicity profile
Figure 1. Sign of efficacy and dose levels in phase 1 oncology
trials.
doi:10.1371/journal.pone.0016633.g001
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Dramatic examples, reminded clinicians that toxicity remains a
major endpoint in MTA phase 1 trials [15–18]. On the other
hand, some recent drugs have been successfully developed without
reaching MTD (e.g. Trastuzumab, Rituximab). The optimal dose
also remains questionable at late development stages for other
drugs (e.g. Sunitinib [19], Sorafenib [20], Imatinib [21]). Some
reasons might limit the assessment of MTD in contemporary trials:
(i) MTD might never be reached given that some of the MTA’s
adverse events do not fulfill the traditional DLT criteria (e.g.:
hematotoxicity, nausea…) but rather represent ‘‘organ-type’’
toxicities that are difficult to predict [22] (ii) To push the drug
dose up to the MTD might not lead to greater clinical or biological
effects since MTA could not exhibit dose dependant toxicity or
efficacy profiles [6–7]. Several biological concepts may explain this
fact. For instance, the binding of monoclonal agents to their
specific epitopes is a saturable system [23–24]. Increasing their
dose would not lead to a gain in efficacy when the plateau is
reached [23]. Moreover, to increase the dose of protein kinase
inhibitors would decrease their specificity and render hazardous
the effect they are supposed to play [25]. Finally, both investigators
and industrials might opt to prematurely stop the assay before the
MTD level in order to limit substantial time and resource
consuming process. New biological endpoints (i.e: effective
inhibition of the molecular target) have been proposed to supplant
classical toxicity endpoints but remain investigational. To date, no
biomarker has yet been validated as a consensual endpoint for
MTA phase 1 trials. [5;26–27].
A similar proportion of trials reporting signs of efficacy was
herein observed, whatever the treatment type (conventional
cytotoxics vs. MTA). This finding is consistent with the landmark
11,000-patient study reported by Horstmann et al, describing
similar non progression rates among patients enrolled in phase 1
trials investigating cytotoxic chemotherapy alone (45,2%) and
MTA alone: immunomodulator (46,8%), receptor or signal
transduction inhibitor (42,4%), antiangiogenic agent (34,9%)
[28]. Such similar high clinical benefit rate could however be
secondary to the favored enrollment of patients with ‘‘low-
progressive’’ disease. Indeed, the huge number of eligibility criteria
implies to select patients with very healthy condition, without any
Table 1. Sign of efficacy and MTD in 317 phase 1 oncology trials.
Trials investigating Conventional
cytotoxic agents
Trials investigating molecular
targeted agents
Trials investigating combination of
both
MTD established
no. (%) 152/201 (75.6) * 38/74 (51.3) 18/42 (42.8)
[95%-CI] [69.7–81.5] [39.9–62.7] [27.8–57.8]
Dose-level associated with DMT
Median 5 5 4
Range 1–13 1–16 1–12
Sign of efficacy
no. (%) 165/201 (82.0) 58/74 (78.3) 31/42 (73.8)
[95%-CI] [76.7–87.4] [69.8–87.7] [60.5–87.7]
Dose-level associated with first
sign of efficacy
Median 1 1 1
Range 1–7 1–9 1–3
First sign of efficacy seen at
the first dose-level
no. (%) 57/109 (52.2) 15/60 (25.0) * 16/31 (51.6)
[95%-CI] [42.9–61.6] [14.0–35.9] [34.0–69.2]
First sign of efficacy seen at
the first 3 dose-levels
no. (%) 81/109 (74.3) 29/60 (48.3) * 19/31 (61.3)
[95%-CI] [66.1–82.5] [35.6–60.9] [44.1–78.4]
First sign of efficacy seen
before MTD
no. (%) 91/144 (63.2) 27/44 (61.3) 13/25 (52.0)
[95%-CI] [55.3–71.0] [46.9–75.7] [32.4–71.6]
Sign of efficacy without
MTD reached
no. (%) 26/193 (13.4) 10/66 (15.0) 21/32 (65.6) *
[95%-CI] [8.6–18.3] [6.5–23.8] [49.1–82.0]
MTD: dose maximal tolerated dose;
*: p,0.05.
The total of trials within the same treatment categories could differ in the different lines because no data concerning MTD was available in 28 trials and because the first
sign of efficacy was not linked to a dose-level in 64 trials.
doi:10.1371/journal.pone.0016633.t001
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functions. The industrial sponsors pressure under investigators
could also favor this trend. Recently, pre-treatment growth
dynamics were demonstrated to have major impact on the
RECIST tumor evaluation [29]. In this context, contemporary
phase 1 trials should include the assessment of tumor growth
kinetics before the administration of the experimental regimens.
The fact that combination phase 1 trials achieve sign of efficacy
before MTD in the largest proportion is not surprising. By these
studies, most investigators assume that the adjunction of a new
drug (i.e.: molecular targeted agent) will improve the antitumoral
effect of an already efficient drug (i.e.: conventional cytotoxic).
Then, some characteristics of the companion cytotoxic (i.e.: the
nature of the drug confronted to the patient’s tumor types, the
starting dose and the incremental scheme adopted) could strongly
influence their efficacy profile. Unfortunately, this retrospective
view does not allow us to correlate the dose response profile with
these probable associated factors.
This study presents nevertheless some limitations due to its
retrospective nature and the fact we used published data. Our
sample of studies is heterogeneous in term of agents investigated
and types of cancer. The lack of uniform reporting standard and
publication biases may also contribute to misestimate the real
clinical benefit. Moreover, our study was not designed to
discriminate different subsets among the trials testing molecular
targeted agents. For instance, monoclonal antibodies would
certainly differ form other agents (e.g.: tyrosine kinase inhibitors,
proteasome inhibitors, vascular disrupting agents) due to their
particular pharmacological properties. Of note, such assessment is
currently ongoing on prospective individual data. Further, the
definition of first sign of efficacy could be discussed: results would
certainly be different if only CR and PR were taken in account for
its definition. However, to consider SD as a proof of efficacy is
relevant since a large body of literature reports that MTA rather
induce stable disease than tumor volume shrinkage [4–5]. Finally,
the fact that more and more patients benefit from tumor molecular
profiling has to be noticed. Phase 1 trials are then being enriched
with tumors harboring the molecular aberrations that are more
susceptible to respond to the tested drug (e.g.: the inclusion of
tumors with PTEN deletion or PIK3CA mutation in mTOR
inhibitors trials). This phenomenon could have an unexpected
impact on the dose finding process. For example, exquisite
responses could be observed at a very low dose level.
Although the concept of optimal biological dose (OBD) was
recently introduced, it has only rarely been used in practice for
dose seeking [22;26]. Several facts explain this situation. First,
pharmacokinetic and pharmacodynamic data are often limited by
technical problems and are mostly addressed with delay (i.e.:
usually after the recommended dose is found). Secondly, the small
amount of patients per dose level renders difficult to correlate the
biological surrogate with the drug concentration. Given the very
restricted number of published trials using OBD to determine the
recommended phase 2 dose, we could not explore if signs of
efficacy were observed earlier in these trials.
Signs of efficacy are described in most phase 1 oncology trials.
When investigating molecular targeted agents alone, first signs of
efficacy are less frequently observed at the early dose levels, and
MTD are less frequently reached. The present report points out
the necessity to refine the classical designs in the era of molecular
targeted therapies. Binary primary endpoints including both
tolerability and efficacy (objective response and long-lasting stable
disease) are warranted. The implementation of new approaches
for choosing the starting dose and of accelerated titration designs
could avoid the treatment of patients at under optimal dose.
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